EGOT and breast carcinoma: Analyses of clinical breast cancer samples have shown that patients with low EGOT expression have a high level of paclitaxel resistance and that EGOT may be utilized as a diagnostic biomarker of paclitaxel treatment for breast cancer patients after surgery [46].